Independent Portfolio Consultants’s Corcept Therapeutics CORT Stock Holding History

Independent Portfolio Consultants’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	$12K	Buy	+1,020	New	+$11.1K	0.01%	677

Other funds holding CORT

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

MWNA

Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return

Independent Portfolio Consultants's CORT Position: Q2 2017 in Review

Independent Portfolio Consultants opened a new position in Corcept Therapeutics (CORT) in Q2 2017: 1,020 shares worth $12K. The stake represents 0.01% of the portfolio and ranks #677 among its holdings.

156 funds tracked by Wall St. Rank hold CORT as of Q2 2017.

Independent Portfolio Consultants held 1,020 shares of Corcept Therapeutics worth $12K as of Q2 2017.
Corcept Therapeutics was a new Independent Portfolio Consultants position in Q2 2017.
Corcept Therapeutics made up 0.01% of Independent Portfolio Consultants's portfolio in Q2 2017, its #677 holding.
156 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2017.

Based on Independent Portfolio Consultants's 13F filing for Q2 2017, filed 6 Jul 2017.